問卷

TPIDB > Search Result

Search Result

篩選

List

17Cases

2025-03-01 - 2030-02-01

Phase III

Active
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
  • Condition/Disease

    Gastric Cancer 、Gastroesophageal Junction Cancer

  • Test Drug

    Frozen Crystal Injection Frozen Crystal Injection Injection Injection Injection Film-Coated Tablets Injection

Participate Sites
5Sites

Recruiting5Sites

2019-11-01 - 2024-05-13

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2020-12-15 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-11-01 - 2027-06-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-01-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-10-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2022-12-01 - 2024-10-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-12-31 - 2026-03-18

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

Terminated1Sites

2024-06-01 - 2030-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-08-10 - 2026-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2